



EDELIRIS announces collaboration with MERCK SERONO in Fragment Based Drug Discovery

Lyon – September 27, 2010 - EDELIRIS announced today that they have signed collaboration with Merck Serono, a division of Merck KGaA, Darmstadt, Germany, aiming at the delivery of innovative and exclusive chemical entities for Fragment-Based Drug Discovery (FBDD).

"We are pleased to be collaborating again with Merck Serono on cutting-edge discovery technologies," said Dr. Jean-Yves Ortholand, CEO of Edelris. "Edelris has acquired a unique expertise in the synthesis of biorelevant innovative fragments maximizing 3D-diversity. Our platform has been developed to explore targeted or diversified spaces aiming at providing fragments with high potential for molecular interactions" added Dr. Didier Roche, VP Strategy and Innovation at Edelris.

Fragment based drug discovery has emerged as a powerful approach in identifying new hit-structures over the past years and Edelris significantly contributes to this innovative field through its non-exclusive and exclusive offers.

About Edelris:

EDELIRIS is a MedChem-oriented Research & Service based company, dedicated to the design and production of innovative, therapeutically relevant, natural-mimetic screening compounds. Aiming at the acceleration of the hit/lead discovery process in pharmaceutical and biotech research organizations, EDELIRIS uses its track-proven chemistry and drug discovery expertise to provide novelty to its customers with exclusive or non-exclusive small molecules and with efficient hit/lead optimization capabilities.

Several customers from pharmaceutical and biotechnology companies worldwide have already recognized the value and specificity of Edelris offer, accessing either its experienced MedChem services or its innovative natural-mimetic Keychemical Collections™ and Smart Fragment structures for FBDD.

Contact: Jean-Yves Ortholand
Phone: +33 (0)4 37 56 19 01
Email: jean-yves.ortholand@edelris.com
Web: www.edelris.com